Target intelligence / Profile preview

Ubiquitin carboxyl-terminal hydrolase 11 (USP11)

Target
USP11
Molecular classification
Enzyme, Deubiquitinating enzyme (DUB), Ubiquitin-specific protease family (USP family), C19 cysteine protease subfamily
01

Overview

Ubiquitin carboxyl-terminal hydrolase 11 (USP11) is an enzyme encoded by the USP11 gene in humans and is a member of the largest subfamily of deubiquitinating enzymes (DUBs), specifically the ubiquitin-specific proteases (USPs). USP11 mediates the removal of ubiquitin from protein targets, reversing ubiquitin-mediated protein degradation and modulating diverse cellular processes such as DNA repair, cell cycle regulation, apoptosis, transcription, and signal transduction. It consists of distinct structural domains, including a DUSP domain and multiple ubiquitin-like (UBL) domains, conferring substrate recognition and regulatory capacity. USP11 plays a dual role in tumor biology, participating both in DNA repair and cellular stress responses, which makes it a potential—but complex—therapeutic target in oncology and other diseases linked to genomic instability or dysregulated proteostasis.

Other names
Ubiquitin-specific protease 11UHX1
02

Mechanism of action

Drugs or molecular agents targeting USP11 would act as enzyme inhibitors or activators, affecting the deubiquitination of substrate proteins, altering cellular protein stability and signaling

03

Biological functions

Regulation of ubiquitin-mediated protein degradationDNA repair (homologous recombination)Cell cycle regulationSignal transductionProtein deubiquitinationRegulation of apoptosisTumor suppression and promotion context-dependent
04

Disease associations

CancerDNA repair disordersPotential role in retinal diseasesOther cell cycle and genomic instability diseases
05

Safety considerations

USP11 inhibition could disrupt DNA repair, increasing toxicity, genomic instability, or unintended enhancement of cell death in normal cellsOncogenic and tumor-suppressive roles depending on cellular context, raising theoretical concerns for cancer therapy
06

Interacting drugs

No approved drugs or inhibitors currently established for clinical use; research inhibitors may exist but are not well characterized in clinical settings
07

Biomarkers

Changes in USP11 expression or activity are being explored as biomarkers for certain cancers and sensitivity to DNA-damaging agentsBRCA2 stability in homologous recombination-mediated DNA repair is affected by USP11 status

Beyond the preview

Go deeper on Ubiquitin carboxyl-terminal hydrolase 11 (USP11).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ubiquitin carboxyl-terminal hydrolase 11 (USP11).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call